Cortex Pharmaceuticals Inc

The Irvine neuroscience company, which focuses on treatments for neurological and psychiatric disorders, reported a second quarter net loss of $372,000, or 2 cents a share, compared with a net loss of $423,000, or 3 cents a share, for the like period last year. Revenue, which was generated from research support, declined 16% to $836,000 for the three months ended Dec. 31.

Cortex Pharmaceuticals Inc., which has its stock trading over the counter, said Friday it has applied for listing on the Nasdaq market system. The Irvine neuroscience company said in a press release that it has been informed by Nasdaq that the review process may take six to eight weeks.

Cortex Pharmaceuticals Inc.: The Irvine developer of therapies for neurological and psychiatric disorders said it lost $945,600, or 8 cents a share, in the fiscal second quarter, compared with a net loss of $1.3 million, or 14 cents a share, for the same period a year earlier. No revenues were recorded.

Cortex Pharmaceuticals Inc. said Wednesday its stock has been removed from the Nasdaq SmallCap market. The shares, which have been trading below $1 since mid-October, will be traded on the low-profile over-the-counter market. The stock closed Wednesday at 44 cents a share, unchanged. Irvine-based Cortex, a developer of therapies for neurological and psychiatric disorders, has lost money every year this decade.